Breaking News

newtechadvancements.com
viatris inc amplifies board of directors with renowned healthcare visionary 23

Business

Viatris Inc. Amplifies Board of Directors with Renowned Healthcare Visionary

reading

Benjamin Hughes

June 3, 2024 - 10:59 am

reading

Viatris Inc. Welcomes Renowned Healthcare Expert to Board of Directors

PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a leading global healthcare company, revealed the appointment of Rogerio Vivaldi Coelho, M.D., as the latest addition to its Board of Directors today. Dr. Vivaldi is set to contribute to the Board's efforts to fuel the company's growth, particularly through his role on the revitalized Science and Technology Committee.

Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

Proven Expertise for Strategic Advancement

Melina Higgins, Chair of the Board at Viatris, warmly welcomed Dr. Vivaldi, expressing full confidence in his extensive experience and successful career. "Dr. Vivaldi's remarkable skill set and his profound insights will undoubtedly amplify our Board's capabilities, particularly within our Science and Technology Committee," Higgins stated. The company looks forward to leveraging his unique expertise to buttress its strategic initiatives, focusing on amplifying its innovative product offerings and patient impact.

Dr. Vivaldi's illustrious background includes his recent role as President and CEO of Sigilon Therapeutics, Inc., a pioneering cell therapy company committed to diabetes management. His leadership continued until the firm's acquisition by pharmaceutical giant Eli Lilly and Company in 2023. His past experiences are a testament to his expertise, having functioned as Executive Vice President and Chief Global Therapeutics Officer at Bioverativ Inc., and Chief Commercial Officer at Spark Therapeutics. In addition, his leadership acumen was on display during his time as CEO of Minerva Neurosciences, Inc.

Before these influential roles, Dr. Vivaldi honed his skills at Genzyme Corporation, overseeing its rare disease business as President and leading their renal & endocrine group. During his tenure, he was instrumental in procuring regulatory approval for over 15 orphan products in more than 20 countries. His medical background is equally illustrious, having obtained his medical degree from Universidade do Rio de Janeiro. Subsequently, he underwent a residency in endocrinology at the Universidade do Estado do Rio de Janeiro and an enriching fellowship at Mount Sinai Hospital Center in New York, where his focus was on Gaucher disease genetics. Dr. Vivaldi also holds an M.B.A. from COPPEAD, Universidade Federal do Rio de Janeiro.

Industry Leader with Vision for Growth

Scott A. Smith, CEO of Viatris, extolled Dr. Vivaldi’s wide-ranging experience and track record, particularly highlighting his pioneering work in launching medicines for rare and orphan diseases that position global franchises for growth. Smith's anticipation of Dr. Vivaldi's board contributions aligns with the company's strategy for an invigorating and prosperous future. Courtesy of Melina Higgins and Scott A. Smith, the excitement for the company's trajectory is palpable.

Dr. Vivaldi voiced his eagerness about his new position, underlining Viatris's global reach and commitment to innovation as well as the deep, personal resonance he feels with the company's vision. "Joining the Viatris Board is both an honor and an incredible alignment with my lifelong dedication to making high-quality medicines universally accessible," Dr. Vivaldi remarked. His personal mission to improve patient care worldwide mirrors the company's efforts to deliver impactful medicines irrespective of geographic barriers.

About Viatris Inc.

Viatris Inc. (NASDAQ: VTRS) stands at the forefront of the healthcare industry, uniquely positioned to merge the efficacies of both generic and brand medicines, thereby delivering comprehensive healthcare solutions worldwide. Empowerment is at the core of its mission: to enable healthier living throughout every life stage. With a portfolio that spans a wide variety of medicines, a global supply chain capable of reaching individuals in need wherever they may be, and a robust scientific expertise aimed at overcoming ongoing health challenges, Viatris redefines access to healthcare.

The company's headquarters are in the United States, with global centers strategically located in Pittsburgh, Shanghai, and Hyderabad, India. The corporate reach and capabilities ensure that around 1 billion patients annually have access to quality medicines. From supporting life’s beginnings to providing for the elderly, covering acute to chronic conditions, Viatris's influence on the healthcare landscape is profound and ever-growing. Discover more about Viatris’s initiatives and operations at viatris.com and investor.viatris.com, and engage with them on social networks like LinkedIn, Instagram, YouTube, and X (formerly Twitter).

Forward Looking Statements

This announcement contains what are known as "forward-looking statements." These prognostications are, inherently, subject to risks and uncertainties that might deviate actual outcomes from the ones anticipated. These statements look ahead to the company's expansion plans, involving investing in innovative products that promise significant patient benefits and steering Viatris toward an exhilarating future.

Various elements may influence these forward-looking statements, including decisions made by healthcare and pharmaceutical regulators and changes in related laws and regulations both domestically and abroad. Additional factors such as regulatory curbs, legal barriers, and the company's capacity to introduce new products and execute "at-risk" launches might also impact the projections.

Other determinants include Viatris' and its partners' development, manufacturing, and commercialization capabilities, ongoing legal proceedings, strategic initiatives' efficacy and timelines, and divestitures, acquisitions, or restructuring programs may also skew results. Moreover, the company might face challenges in attaining synergies, growth opportunities, and operational efficiencies or confront goodwill or asset impairment charges related to the divestiture or sale of businesses or assets.

  • Word Count: 69 | Total: 988

The company's performance and future financial results might not meet the hopes or projections set out, which could in turn be affected by global health crises, cybersecurity breaches, international operational risks, intellectual property protection challenges, third-party relationship shifts, customer and supplier dynamics, competitive pressures, and overall economic and financial conditions.

These forward-looking statements extended to Viatris' stock price volatility, general economic circumstances, inflation, currency exchange rates, and the company's stock repurchase plans. Such factors epitomize the unpredictable nature of the business climate within which Viatris operates.

It's noteworthy that Viatris judiciously uses its website as a means to disseminate material public information, aligning with the SEC's Regulation Fair Disclosure (Reg FD). All future updates pertinent to these statements will be communicated as per legal requirements.

In conclusion, Viatris Inc. upholds its commitment to providing greater access to quality healthcare solutions across the globe. The incorporation of Dr. Rogerio Vivaldi Coelho into the Viatris Board of Directors is expected to further propel the company towards achieving its aims of delivering transformative healthcare outcomes to patients worldwide. As a custodian of integral corporate information, Viatris reaffirms its promise to maintain transparency and continual disclosure of significant updates to its investors and the public at large.

For more news and insights regarding Viatris Inc., please visit their website or consult their filings with the Securities and Exchange Commission (SEC).

SOURCE: Viatris Inc.